High Ki-67 Expression Predicting a Risk Factor for the Progression of Disease Within 24 Months and Microenvironment in Follicular Lymphoma

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Oct 26

PMID 39456838

Authors

Hinako Narita

Kai Kuroiwa

Yukiko Kawaguchi

So Murai

Yosuke Sasaki

Mayumi Homma

Natsuki Kawamata

Hidenori Hayashi

Kazuki Nagao

Reiko Okamura

Yuka Uesugi

Yohei Sasaki

Shotaro Shimada

Megumi Watanuki

Nana Arai

Kouji Yanagisawa

Eisuke Shiozawa

Toshiko Yamochi

Norimichi Hattori

Affiliations

Soon will be listed here.

Abstract

Most follicular lymphomas (FLs) demonstrate an indolent clinical course with favorable outcomes; however, a fraction of patients experiences progression of disease within 24 months (POD24) and has adverse outcomes. This study aimed to determine the predictive risk factors for POD24 in patients with FL, and the characteristics of the microenvironment in FL with POD24. By multivariate analysis, we revealed that increased Ki-67 expression was associated with POD24 events in patients with FL (hazard ratio [HR]: 6.29, 95% confidence interval [CI]: 1.96-20.22, = 0.0020). Additionally, patients with FL with POD24 demonstrated immune cell reduction by immunohistochemistry analysis. Our results help better understand the therapeutic strategies for FL with POD24.

Citing Articles

Prognostication of Follicular Lymphoma: A Review of Prognostic Scores and Factors.

Jona A, Kiss E, Illes A Diagnostics (Basel). 2025; 15(5).

PMID: 40075894 PMC: 11899216. DOI: 10.3390/diagnostics15050647.

References

Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P . Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997; 15(3):1110-7. DOI: 10.1200/JCO.1997.15.3.1110. View

Advani R, Flinn I, Popplewell L, Forero A, Bartlett N, Ghosh N . CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. N Engl J Med. 2018; 379(18):1711-1721. PMC: 8058634. DOI: 10.1056/NEJMoa1807315. View

Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol. 2009; 27(27):4555-62. DOI: 10.1200/JCO.2008.21.3991. View

Morschhauser F, Nastoupil L, Feugier P, Schiano De Colella J, Tilly H, Palomba M . Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma. J Clin Oncol. 2022; 40(28):3239-3245. PMC: 9553375. DOI: 10.1200/JCO.22.00843. View

Sander B, de Jong D, Rosenwald A, Xie W, Balague O, Calaminici M . The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. Haematologica. 2014; 99(4):715-25. PMC: 3971082. DOI: 10.3324/haematol.2013.095257. View

Mir F, Mattiello F, Grigg A, Herold M, Hiddemann W, Marcus R . Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy. Am J Hematol. 2020; 95(12):1503-1510. PMC: 7756469. DOI: 10.1002/ajh.25973. View

Freeman C, Kridel R, Moccia A, Savage K, Villa D, Scott D . Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019; 134(9):761-764. DOI: 10.1182/blood.2019000258. View

Huet S, Tesson B, Jais J, Feldman A, Magnano L, Thomas E . A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018; 19(4):549-561. PMC: 5882539. DOI: 10.1016/S1470-2045(18)30102-5. View

Sweetenham J, Goldman B, LeBlanc M, Cook J, Tubbs R, Press O . Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study. Ann Oncol. 2009; 21(6):1196-1202. PMC: 2875547. DOI: 10.1093/annonc/mdp460. View

10.

Kawaguchi Y, Shiozawa E, Shimada S, Sasaki Y, Abe M, Murai S . Ki-67 expression of immunohistochemistry using computerized image analysis is a useful prognostic marker in follicular lymphomas. Int J Clin Exp Pathol. 2020; 11(7):3366-3374. PMC: 6962864. View

11.

Blaker Y, Spetalen S, Brodtkorb M, Lingjaerde O, Beiske K, Ostenstad B . The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era. Br J Haematol. 2016; 175(1):102-14. DOI: 10.1111/bjh.14201. View

12.

Nasir A, Hegerova L, Yousaf H, Forster C, Shanley R, Linden M . Digital and manual interfollicular Ki-67 are associated with a progression-free survival in patients with low-grade follicular lymphoma. Am J Clin Pathol. 2023; 161(4):380-387. PMC: 11484579. DOI: 10.1093/ajcp/aqad161. View

13.

Alaggio R, Amador C, Anagnostopoulos I, Attygalle A, de Oliveira Araujo I, Berti E . The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36(7):1720-1748. PMC: 9214472. DOI: 10.1038/s41375-022-01620-2. View

14.

Canioni D, Salles G, Mounier N, Brousse N, Keuppens M, Morchhauser F . High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol. 2007; 26(3):440-6. DOI: 10.1200/JCO.2007.12.8298. View

15.

Rodriguez-Sevilla J, Fernandez-Rodriguez C, Bento L, Diez-Feijoo R, Pinzon S, Gibert J . Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy. Blood Adv. 2022; 7(8):1606-1614. PMC: 10173729. DOI: 10.1182/bloodadvances.2022007949. View

16.

Hu J, Gao F, Zhao J, Song W, Wang Y, Zheng Y . The prognostic index PRIMA-PI combined with Ki67 as a better predictor of progression of disease within 24 months in follicular lymphoma. Front Oncol. 2023; 13:1090610. PMC: 10327599. DOI: 10.3389/fonc.2023.1090610. View

17.

Yang Z, Kim H, Villasboas J, Price-Troska T, Jalali S, Wu H . Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma. Cell Rep. 2019; 26(8):2178-2193.e3. PMC: 6402596. DOI: 10.1016/j.celrep.2019.01.085. View

18.

Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger A, Szczepanowski M . Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015; 16(9):1111-1122. DOI: 10.1016/S1470-2045(15)00169-2. View

19.

Bachy E, Maurer M, Habermann T, Gelas-Dore B, Maucort-Boulch D, Estell J . A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood. 2018; 132(1):49-58. PMC: 6034646. DOI: 10.1182/blood-2017-11-816405. View

20.

Liu L, Yu X, Li Z, He X, Zha J, Lin Z . Revealing the evolution of the tumor immune microenvironment in follicular lymphoma patients progressing within 24 months using single-cell imaging mass cytometry. J Hematol Oncol. 2022; 15(1):115. PMC: 9396877. DOI: 10.1186/s13045-022-01326-z. View